Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients With Relapsed or Refractory Disease
Conditions
Interventions
Bortezomib
Romidepsin
Locations
12
United States
Loma Linda University Cancer Center
Loma Linda, California, United States
Desert Cancer Care, Inc
Rancho Mirage, California, United States
Santa Barbara Hematology Oncology Medical Group, Inc.
Santa Barbara, California, United States
James R Berenson, MD, Inc.
West Hollywood, California, United States
Georgia Cancer Specialists I, PC
Atlanta, Georgia, United States
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Start Date
September 1, 2008
Primary Completion Date
March 1, 2010
Completion Date
March 1, 2010
Last Updated
November 25, 2019
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions